OverviewSuggest Edit

Adaptive Biotechnologies is a company developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its main product, immunoSEQ, uses a proprietary immune profiling assay to analyze T cells and B cells, critical components of the adaptive immune system’s defense against disease. The company develops a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. 

TypePublic
Founded2009
HQSeattle, WA, US
Websiteadaptivebiotech.com
Employee Ratings3.8
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)453(+31%)
Job Openings104
Revenue (FY, 2020)$98.4 M(+16%)
Share Price (Jun 2021)$35.9
Cybersecurity ratingDMore

Key People/Management at Adaptive Biotechnologies

Chad Cohen

Chad Cohen

Chief Financial Officer
Nancy Hill

Nancy Hill

Executive Vice President, Operations & Program Management
Harlan Robins

Harlan Robins

Chief Scientific Officer & Co-Founder
Chad Robins

Chad Robins

Chief Executive Officer, Co-Founder, Chairman of the Board
Stacy Taylor

Stacy Taylor

Senior Vice President, General Counsel
Lance Baldo

Lance Baldo

Chief Medical Officer
Show more

Adaptive Biotechnologies Office Locations

Adaptive Biotechnologies has offices in Seattle, New York and South San Francisco
Seattle, WA, US (HQ)
1551 Eastlake Ave E #200
New York, NY, US
1460 Broadway
South San Francisco, CA, US
2 Tower Pl UNIT 900
Show all (3)

Adaptive Biotechnologies Financials and Metrics

Adaptive Biotechnologies Revenue

Embed Graph
View revenue for all periods
Adaptive Biotechnologies's revenue was reported to be $98.38 m in FY, 2020
USD

Revenue (Q1, 2021)

38.4m

Gross profit (Q1, 2021)

28.5m

Gross profit margin (Q1, 2021), %

74%

Net income (Q1, 2021)

(40.6m)

EBIT (Q1, 2021)

(41.3m)

Market capitalization (4-Jun-2021)

5.0b

Closing stock price (4-Jun-2021)

35.9

Cash (31-Mar-2021)

173.6m

EV

5.0b
Adaptive Biotechnologies's current market capitalization is $5 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

38.4m55.7m85.1m98.4m

Revenue growth, %

45%

Cost of goods sold

15.7m19.7m22.3m22.5m

Gross profit

22.8m36.0m62.8m75.9m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

22.1m26.1m20.9m21.0m26.3m38.4m

Cost of goods sold

5.7m5.6m5.3m4.9m6.1m10.0m

Gross profit

16.4m20.5m15.6m16.1m20.2m28.5m

Gross profit Margin, %

74%79%74%77%77%74%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

83.3m55.0m96.6m123.4m

Accounts Receivable

5.6m4.8m12.7m10.0m

Prepaid Expenses

2.7m3.1m14.1m14.5m

Inventories

4.8m7.8m9.1m14.1m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

48.5m74.9m212.7m365.4m497.1m173.6m

Accounts Receivable

7.3m9.3m9.4m7.9m11.9m19.8m

Prepaid Expenses

4.0m10.0m9.6m10.7m19.7m13.5m

Inventories

8.0m8.7m10.5m10.5m10.7m17.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(42.8m)(46.4m)(68.6m)(146.2m)

Depreciation and Amortization

5.8m6.0m1.7m8.5m

Inventories

(2.7m)(3.0m)(1.2m)(5.0m)

Accounts Payable

(1.5m)2.2m6.1m7.5m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(34.0m)(48.0m)(31.4m)(64.9m)(101.7m)(40.6m)

Depreciation and Amortization

3.7m5.7m2.0m4.0m6.1m2.7m

Inventories

(166.0k)(829.0k)(1.4m)(1.5m)(1.7m)(3.4m)

Accounts Payable

1.3m3.1m(4.6m)(1.9m)30.0k(7.3m)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Adaptive Biotechnologies Operating Metrics

FY, 2018

Immune Receptors Characteristics in Database

20 b

Partners

125

Product Lines

2
Show all operating metrics

Adaptive Biotechnologies Revenue Breakdown

Embed Graph

Adaptive Biotechnologies revenue breakdown by business segment: 59.2% from Sequencing revenue and 40.8% from Development revenue

Adaptive Biotechnologies Cybersecurity Score

Cybersecurity ratingPremium dataset

D

61/100

SecurityScorecard logo

Adaptive Biotechnologies Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Adaptive Biotechnologies Online and Social Media Presence

Embed Graph

Adaptive Biotechnologies Company Culture

  • Overall Culture

    B

    73/100

  • CEO Rating

    A+

    78/100

  • Compensation

    C-

    63/100

  • Diversity

    D+

    63/100

Learn more on Comparably

Adaptive Biotechnologies News and Updates

Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences

SEATTLE, May 20, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating vi…

Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen

SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointments of Lesl…

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19

Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference

SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating i…

Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio

SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an expansion of its colla…

Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection

T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA)
Show more

Adaptive Biotechnologies Blogs

T Cells: The Unsung Heroes of the Immune System

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Harlan Robins, PhD, Chief Scientific Officer and Co-founder As the world strives to put the pandemic behind us, a burden of uncertainty continues to weigh on the minds of patients, physicians, and scientists. How…

One Patient’s Journey to a Lyme Disease Diagnosis

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Laura Cooper, Senior Director, Corporate Communications Earlier this spring, my oldest son spent a week with my parents in the Berkshires – a welcome break for our entire family after an intense winter of togethe…

3 Things the COVID Pandemic has Taught Us About Immunity

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Lance Baldo, Chief Medical Officer Adaptive Biotechnologies and the Personalized Medicine Coalition (PMC) co-hosted a congressional briefing to explore the rapidly emerging knowledge about the role of the adaptiv…

A Conversation with Jenny Ahlstrom of Myeloma Crowd about Multiple Myeloma, MRD and the Changing Treatment Landscape

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Susan Bobulsky, SVP, Diagnostics, clonoSEQ & Jenny Ahlstrom, Founder, Myeloma Crowd In March 2021, the blood cancer community celebrated a big win for those living with multiple myeloma (MM) with the FDA appr…

Celebrating Our Lab Professionals During Medical Laboratory Professionals Week – and Every Week

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Stephanie Hallam, Ph.D., VP Molecular Lab Operations, Head Clinical Laboratory Director “By enabling this exploration of the human adaptive immune universe, Adaptive is powering the age of immune medicine to ulti…

Reclaiming women’s progress post-pandemic

SHARE THIS ARTICLE: Share on email Share on twitter Share on linkedin Share on facebook Mary Pat Lancelotta, Corporate Marketing and Communications For just a few months in late 2019/early 2020, for the first time in history, the number of women in the workforce overtook the number of men. What an i…
Show more

Adaptive Biotechnologies Frequently Asked Questions

  • When was Adaptive Biotechnologies founded?

    Adaptive Biotechnologies was founded in 2009.

  • Who are Adaptive Biotechnologies key executives?

    Adaptive Biotechnologies's key executives are Chad Cohen, Nancy Hill and Harlan Robins.

  • How many employees does Adaptive Biotechnologies have?

    Adaptive Biotechnologies has 453 employees.

  • What is Adaptive Biotechnologies revenue?

    Latest Adaptive Biotechnologies annual revenue is $98.4 m.

  • What is Adaptive Biotechnologies revenue per employee?

    Latest Adaptive Biotechnologies revenue per employee is $217.2 k.

  • Who are Adaptive Biotechnologies competitors?

    Competitors of Adaptive Biotechnologies include Personalis, AlloVir and Proteus Digital Health.

  • Where is Adaptive Biotechnologies headquarters?

    Adaptive Biotechnologies headquarters is located at 1551 Eastlake Ave E #200, Seattle.

  • Where are Adaptive Biotechnologies offices?

    Adaptive Biotechnologies has offices in Seattle, New York and South San Francisco.

  • How many offices does Adaptive Biotechnologies have?

    Adaptive Biotechnologies has 3 offices.